{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:20:21Z","timestamp":1792704021869,"version":"4.5.0"},"reference-count":38,"publisher":"European Respiratory Society (ERS)","issue":"1","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019832","name":"Gal\u00e1pagos","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019832","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,7,31]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Idiopathic pulmonary fibrosis (IPF) is characterised by progressive loss of pulmonary function and poor survival. Although biomarkers for disease progression and mortality exist, their reliability in large studies remains unproven. This study investigates prognostic biomarkers from the ISABELA trials, the largest IPF cohort to date, to identify those predicting worse clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Plasma from 1280 IPF patients in ISABELA 1 and 2 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03711162\">NCT03711162<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03733444\">NCT03733444<\/jats:ext-link>\n                      ) was analysed for 17 circulating soluble disease-related biomarkers at multiple time-points and for the\n                      <jats:italic>MUC5B<\/jats:italic>\n                      (rs35705950_T) genotype. Statistical learning algorithms investigated biomarker levels\/status with disease progression (\u226510% decline in forced vital capacity (FVC) or mortality within 1\u2005year) and pharmacotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients with \u226510% annual decline in FVC had higher median baseline of matrix metalloproteinase-7 (MMP-7)\n                      <jats:italic>versus<\/jats:italic>\n                      those with &lt;10% decline (5.5\n                      <jats:italic>versus<\/jats:italic>\n                      4.2\u2005\u00b5g\u00b7L\n                      <jats:sup>\u22121<\/jats:sup>\n                      ; p&lt;0.005). Patients with baseline MMP-7 \u22655.2\u2005\u03bcg\u00b7L\n                      <jats:sup>\u22121<\/jats:sup>\n                      and\/or C-C motif chemokine ligand 18 (CCL18) \u226575.2\u2005\u03bcg\u00b7L\n                      <jats:sup>\u22121<\/jats:sup>\n                      had increased risk of mortality (p&lt;0.0001); with patients having both elevated biomarkers at an even greater risk. Machine learning identified CCL18 changes by week 26 as a predictor of disease progression. The rs35705950_T genotype predicted neither mortality nor disease progression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We provide new insights into the prognostic value of MMP-7 and CCL18 in identifying high-risk IPF patients in the largest cohort to date. The combination of high baseline MMP-7 and CCL18 levels, along with longitudinal changes in CCL18, has the potential to enhance risk stratification and support efficacy assessment and monitoring in clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/23120541.00893-2025","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T16:55:27Z","timestamp":1757609727000},"page":"00893-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Prognostic biomarkers for idiopathic pulmonary fibrosis: findings from ISABELA clinical trials"],"prefix":"10.1183","volume":"12","author":[{"given":"Matthew J.","family":"Randall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus A.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"de Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5917-4601","authenticated-orcid":false,"given":"Naftali","family":"Kaminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlene","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7192-9149","authenticated-orcid":false,"given":"Toby M.","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niyati","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7336-7458","authenticated-orcid":false,"given":"Antje","family":"Prasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Pujuguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Teneggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernt","family":"van den Blink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4951-1867","authenticated-orcid":false,"given":"Louise V.","family":"Wain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9648-3497","authenticated-orcid":false,"given":"Wim","family":"Wuyts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmina","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"2026021601451044000_12.1.00893-2025.1","doi-asserted-by":"publisher","DOI":"10.1159\/000504763"},{"key":"2026021601451044000_12.1.00893-2025.2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba1983"},{"key":"2026021601451044000_12.1.00893-2025.3","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aba1972"},{"key":"2026021601451044000_12.1.00893-2025.4","doi-asserted-by":"publisher","DOI":"10.1164\/RCCM.201712-2410OC\/SUPPL_FILE\/DISCLOSURES.PDF"},{"key":"2026021601451044000_12.1.00893-2025.5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1164\/rccm.202003-0669OC","article-title":"Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis","volume":"204","author":"Kreuter","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021601451044000_12.1.00893-2025.6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S2213-2600(18)30185-1","article-title":"Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials","volume":"6","author":"Neighbors","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2026021601451044000_12.1.00893-2025.7","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1164\/rccm.200509-1518OC","article-title":"A vicious circle of alveolar macrophages and fibroblasts perpetuates pulmonary fibrosis via CCL18","volume":"173","author":"Prasse","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021601451044000_12.1.00893-2025.8","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200808-1201OC"},{"key":"2026021601451044000_12.1.00893-2025.9","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201101-0058OC"},{"key":"2026021601451044000_12.1.00893-2025.10","doi-asserted-by":"publisher","DOI":"10.1186\/s40064-015-1455-z"},{"key":"2026021601451044000_12.1.00893-2025.11","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00074-2016"},{"key":"2026021601451044000_12.1.00893-2025.12","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/resp.12920","article-title":"Validation of the prognostic value of MMP-7 in idiopathic pulmonary fibrosis","volume":"22","author":"Tzouvelekis","year":"2017","journal-title":"Respirology"},{"key":"2026021601451044000_12.1.00893-2025.13","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2213-2600(17)30387-9","article-title":"Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study","volume":"5","author":"Allen","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026021601451044000_12.1.00893-2025.14","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12931-021-01694-z","article-title":"Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment","volume":"22","author":"Biondini","year":"2021","journal-title":"Respir Res"},{"key":"2026021601451044000_12.1.00893-2025.15","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.5355"},{"key":"2026021601451044000_12.1.00893-2025.16","unstructured":"Woolson RF . Wilcoxon signed-rank test. In: D'Agostino RB , Sullivan L , Massaro J , eds. Wiley Encyclopedia of Clinical Trials. Hoboken, NJ, John Wiley & Sons, 2013."},{"key":"2026021601451044000_12.1.00893-2025.17","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4028\/www.scientific.net\/AMM.611.115","article-title":"Methodology and application of the Kruskal\u2013Wallis test","volume":"611","author":"Ostertagov\u00e1","year":"2014","journal-title":"Appl Mech Mat"},{"key":"2026021601451044000_12.1.00893-2025.18","doi-asserted-by":"publisher","DOI":"10.1177\/1536867X1501500117"},{"key":"2026021601451044000_12.1.00893-2025.19","doi-asserted-by":"crossref","unstructured":"MacFarland TW , Yates JM . Introduction to Nonparametric Statistics for the Biological Sciences Using R. Cham, Springer, 2016.","DOI":"10.1007\/978-3-319-30634-6"},{"key":"2026021601451044000_12.1.00893-2025.20","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0951-8320(94)90010-8","article-title":"Proportional hazards model: a review","volume":"44","author":"Kumar","year":"1994","journal-title":"Reliab Eng Syst Saf"},{"key":"2026021601451044000_12.1.00893-2025.21","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1164\/rccm.202008-3211LE","article-title":"Proportion of idiopathic pulmonary fibrosis risk explained by known common genetic loci in European populations","volume":"203","author":"Leavy","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021601451044000_12.1.00893-2025.22","doi-asserted-by":"publisher","DOI":"10.1038\/nature15393"},{"key":"2026021601451044000_12.1.00893-2025.23","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-1002"},{"key":"2026021601451044000_12.1.00893-2025.24","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S2213-2600(17)30430-7","article-title":"An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study","volume":"5","author":"Maher","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026021601451044000_12.1.00893-2025.25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01612-2021"},{"key":"2026021601451044000_12.1.00893-2025.26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/resp.14231","article-title":"Predictors of mortality in subjects with progressive fibrosing interstitial lung diseases","volume":"27","author":"Brown","year":"2022","journal-title":"Respirology"},{"key":"2026021601451044000_12.1.00893-2025.27","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02279-2019"},{"key":"2026021601451044000_12.1.00893-2025.28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2026021601451044000_12.1.00893-2025.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.04.066"},{"key":"2026021601451044000_12.1.00893-2025.30","first-page":"A3685","article-title":"Development of a multi-biomarker assay for serum proteins by the prognostic lung fibrosis consortium (PROLIFIC)","volume":"209","author":"Schafer","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"2026021601451044000_12.1.00893-2025.31","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.3390\/jcm9061993","article-title":"Genetic variation in CCL18 gene influences CCL18 expression and correlates with survival in idiopathic pulmonary fibrosis\u2013Part B","volume":"9","author":"Caliskan","year":"2020","journal-title":"J Clin Med"},{"key":"2026021601451044000_12.1.00893-2025.32","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.3390\/jcm9061940","article-title":"Genetic variation in CCL18 gene influences CCL18 expression and correlates with survival in idiopathic pulmonary fibrosis: part A","volume":"9","author":"Wiertz","year":"2020","journal-title":"J Clin Med"},{"key":"2026021601451044000_12.1.00893-2025.33","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S2213-2600(22)00251-X","article-title":"Longitudinal lung function and gas transfer in individuals with idiopathic pulmonary fibrosis: a genome-wide association study","volume":"11","author":"Allen","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2026021601451044000_12.1.00893-2025.34","doi-asserted-by":"publisher","DOI":"10.1111\/ahg.12522"},{"key":"2026021601451044000_12.1.00893-2025.35","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00019-2016"},{"key":"2026021601451044000_12.1.00893-2025.36","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/cpt.3138","article-title":"ISABELA studies: plasma exposure and target engagement do not explain the lack of efficacy of ziritaxestat in patients with idiopathic pulmonary fibrosis","volume":"115","author":"Taneja","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2026021601451044000_12.1.00893-2025.37","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.3390\/jcm10173864","article-title":"Serial measurements of circulating KL-6, SP-D, MMP-7, CA19-9, CA-125, CCL18, and periostin in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy: an exploratory study","volume":"10","author":"Majewski","year":"2021","journal-title":"J Clin Med"},{"key":"2026021601451044000_12.1.00893-2025.38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0116775"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00893-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:45:19Z","timestamp":1771235119000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00893-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,16]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1183\/23120541.00893-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00893-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]}}}